Personal information

Emails & domains

Verified email domains

Activities

Collapse all

Funding (11)

Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and economic analysis

2021-08-01 to 2023-07-31 | Grant
NIHR Evaluation Trials and Studies Coordinating Centre (Southampton, GB)
URL: https://app.dimensions.ai/details/grant/grant.9959342
GRANT_NUMBER: NIHR132948
Source: Self-asserted source
Mark Crawford Simmonds via DimensionsWizard

Early CDT-Lung for assessing malignancy risk of indeterminate pulmonary nodules

2021-01-19 to 2021-10-20 | Grant
National Institute for Health Research (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.9959511
GRANT_NUMBER: NIHR133496
Source: Self-asserted source
Mark Crawford Simmonds via DimensionsWizard

OTL-200 for treating metachromatic leukodystrophy (ID1666)

2020-11-25 to 2021-04-15 | Grant
National Institute for Health Research (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.9613551
GRANT_NUMBER: NIHR131943
Source: Self-asserted source
Mark Crawford Simmonds via DimensionsWizard

Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (ID1658)

2020-08-13 to 2021-02-11 | Grant
National Institute for Health Research (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.9614210
GRANT_NUMBER: NIHR131929
Source: Self-asserted source
Mark Crawford Simmonds via DimensionsWizard

Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]

2019-12-12 to 2021-03-02 | Grant
National Institute for Health Research (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.9614197
GRANT_NUMBER: NIHR130708
Source: Self-asserted source
Mark Crawford Simmonds via DimensionsWizard

Larotrectinib for treating advanced solid tumours with TRK fusions [ID1299]

2019-06-05 to 2019-11-20 | Grant
National Institute for Health Research (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.9614154
GRANT_NUMBER: NIHR127895
Source: Self-asserted source
Mark Crawford Simmonds via DimensionsWizard

Tisagenlecleucel-T for previously treated B-cell acute lymphoblastic leukaemia in people aged 3 to 25 at initial diagnosis [ID1167]

2018-05-30 to 2018-08-22 | Grant
National Institute for Health Research (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.9614099
GRANT_NUMBER: 17/141/10
Source: Self-asserted source
Mark Crawford Simmonds via DimensionsWizard

Tisagenlecleucel-T for treating relapsed or refractory diffuse large B-cell lymphoma [ID1166]

2018-05-30 to 2018-08-22 | Grant
National Institute for Health Research (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.9614098
GRANT_NUMBER: 17/141/09
Source: Self-asserted source
Mark Crawford Simmonds via DimensionsWizard

Imaging for detection of osteomyelitis: a systematic review and meta-analysis

2017-07-01 to 2018-09-30 | Grant
NIHR Evaluation Trials and Studies Coordinating Centre (Southampton, GB)
URL: https://app.dimensions.ai/details/grant/grant.9714306
GRANT_NUMBER: 16/103/03
Source: Self-asserted source
Mark Crawford Simmonds via DimensionsWizard

DySIS for cervical cancer (review of DG04 - 11/44/01)

2016-11-22 to 2017-09-26 | Grant
National Institute for Health Research (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.9714224
GRANT_NUMBER: 16/30/01
Source: Self-asserted source
Mark Crawford Simmonds via DimensionsWizard

High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation

2015-10-13 to 2016-08-17 | Grant
National Institute for Health Research (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.9714126
GRANT_NUMBER: 15/17/02
Source: Self-asserted source
Mark Crawford Simmonds via DimensionsWizard

Peer review (4 reviews for 1 publication/grant)

Review activity for Journal of clinical epidemiology. (4)
How many people are using ORCID?